Navigation Links
Plandai Biotechnology, Inc. Enters Into License Agreement With Phyto Nutricare To Develop Nutraceutical Products

SEATTLE, April 22, 2013 /PRNewswire/ -- Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts, today announced that it has entered into a license agreement with Phyto Nutricare PLC, a UK company, which will oversee all aspects of developing and marketing Phytofare™ extracts for nutraceutical applications. 

Under the terms of the agreement, Phyto Nutricare will pay Plandai a one-time license fee of two million dollars (US$2,000,000) and then a recurring payment equal to five percent (5%) of future profits from Phytofare™ product sales.  Sales of Phytofare™ are expected to commence in Q4 of 2013.

Plandai Chief Executive Officer, Roger Duffield commented, "Our foremost goal over the short term is to bring Phytofare™ products to market and begin generating revenues.  Phyto Nutricare is tasked with introducing our products to market in the nutraceutical arena, which covers supplements, food and drink additives, cosmetics, healthcare, and related fields.  This is a multi-billion dollar industry that has heretofore been plagued by ingredients that suffer from a lack of bioavailability.  Botanical extracts are especially prevalent in everything from skin cream to energy drinks. Unfortunately, the way other suppliers produce their extracts results in products that have very little active antioxidant properties and virtually no ability to be absorbed by human tissues."

"Phytofare™, in contrast," explained Mr. Duffield, "is made from living plant material, so we capture the antioxidants while still active.  We then are able to re-arrange the molecular structure of the catechins and reduce them to nano-particle size, resulting in a product that is vastly more absorbable by human cells.  This maximizes the effectiveness of the benefits of green tea and will allow product manufacturers to finally deliver on their health and wellness claims."

"Licensing the development and distribution of Phytofare™ products for the nutraceutical industry to Phyto Nutricare allows Plandai to focus on the development of new extractions and the pursuit of pharmaceutical drug targets," Mr. Duffield added.

Phyto Nutricare further cemented this relationship by appointing Callum Baylis-Duffield as its President and Chief Executive Officer.  Mr. Baylis-Duffield serves on the Board of Directors of Plandai and holds the position of Vice President of Sales and Marketing.  He is a graduate in International Business with French (BA Hons) from the University of the West of England. From 2007-2010, he was employed by Johnson and Johnson UK as a marketing & sales manager of a proprietary surgical device. Mr. Baylis-Duffield has been involved with the research and development of the Plandai's proprietary emulsions since 2004 and has worked extensively with the USA scientific team.

Mr. Baylis-Duffield commented, "I'm excited to be back in the UK to head up the introduction of Phytofare™ extracts to the nutraceutical market.  Our immediate objective is to complete the final product profiling and testing and then formalize our sales and distribution channels so that we are positioned for maximum market penetration once the first product is available.  My job is made easier by having extracts that have greater purity, superior anti-oxidant properties and unmatched bioavailability."

Plandai expects to shortly commence a human clinical trial to targeting bioavailability, obesity, high cholesterol, hypertension and high blood pressure, with results expected in late Q3.   

About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc. and its subsidiaries, focus on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the health and wellness industry.  Its principle holdings consist of land, farms and infrastructure in South Africa.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandai's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandai is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Andrew Beyer 
Phone: 619-202-7456 

SOURCE Plandai Biotechnology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Plandai Biotechnology, Inc. Updates Progress Of Preparing Products For Market
2. DuPont Pioneer and Mendel Biotechnology, Inc. Collaborate to Improve Water Use Efficiency and Photosynthesis in Corn
3. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
4. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
5. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
6. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
7. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
8. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
9. Centers for Medicare & Medicaid Services Win 2012 National Cybersecurity Innovation Award
10. Nu Skin Enterprises Enters Into Agreement To Acquire NOX Technologies
11. Eqalix Enters Sponsored Research Agreement with Temple University
Post Your Comments:
(Date:10/13/2015)... Oct. 13, 2015 PharmaCyte Biotech, Inc. (OTCQB: PMCB) ... volume was at near average with 1,308,352 shares being traded. ... this year hitting a low of $.072 in September, then ... --> Our due diligence will show investors in ... Get our report by using the link below at no ...
(Date:10/13/2015)... ... October 13, 2015 , ... InSphero AG , the ... cell culture models, has launched a 14 Day Hepatotoxicity Testing Service ... Human Liver Microtissues. The service streamlines toxicity testing of compounds in InSphero’s ...
(Date:10/13/2015)... DE (PRWEB) , ... October 13, 2015 , ... ... its new President. Steve joins as the Pistoia Alliance continues to drive to ... , The non-profit Pistoia Alliance is focusing its vision and expanding its work ...
(Date:10/13/2015)... , Oct. 13 2015 Research and ... "US & Europe Markets for Bone Morphogenetic Protein ... to their offering. --> ... that induce the formation of bone after a fracture. ... embryonic development in the formation of the skeleton. There ...
Breaking Biology Technology:
(Date:10/13/2015)... , Oct. 13, 2015 Feedzai ... learning to analyze big data and minimize risk in ... Emailage , an innovative fraud prevention solution that ... risk based on a user,s email address. The two ... learning solution that combines email risk assessment with fraud ...
(Date:10/13/2015)... , October 13, 2015 Dragon ... tech companies in China , announced today ... Limited ("Yazheng"), has received a contract for Multi-Format Naked Eye ... awarded Yazheng approximately $450,000 for the project that is expected ... achieve 30% to 35% in gross profits. ...
(Date:10/13/2015)... , Oct. 7, 2015 Research and ... the "India Biometrics Authentication & Identification Market - ... --> --> ... $823.46 million in 2014 to $2.06 billion in 2020 ... 2020. India . Growing ...
Breaking Biology News(10 mins):